These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27920517)

  • 21. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H; Disse B; Rodriguez-Roisin R; Kirsten A; Watz H; Tetzlaff K; Towse L; Finnigan H; Dahl R; Decramer M; Chanez P; Wouters EF; Calverley PM;
    N Engl J Med; 2014 Oct; 371(14):1285-94. PubMed ID: 25196117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Number needed to treat: enigmatic results for exacerbations in COPD.
    Suissa S
    Eur Respir J; 2015 Apr; 45(4):875-8. PubMed ID: 25829430
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD.
    Perng DW; Tao CW; Su KC; Tsai CC; Liu LY; Lee YC
    Eur Respir J; 2009 Apr; 33(4):778-84. PubMed ID: 19129278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tiotropium: a new therapeutic option in asthma.
    Novelli F; Costa F; Latorre M; Malagrinò L; Celi A; Vagaggini B; Paggiaro P
    Monaldi Arch Chest Dis; 2013; 79(3-4):109-15. PubMed ID: 24761528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical improvement by tiotropium plus olodaterol.
    Tamura T; Kagohashi K; Satoh H
    Respir Med; 2017 Apr; 125():104. PubMed ID: 27017081
    [No Abstract]   [Full Text] [Related]  

  • 27. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
    Calverley PMA; Stockley RA; Seemungal TAR; Hagan G; Willits LR; Riley JH; Wedzicha JA;
    Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of tiotropium on symptoms of chronic obstructive pulmonary disease in a patient with chronic heart failure.
    Olson TP; Johnson BD
    Circ J; 2007 May; 71(5):802; author reply 802-3. PubMed ID: 17476791
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of tiotropium bromide combined with different doses of fluticasone plus salmeterol DPI in the treatment of stable COPD.
    Ma X; Xu J; Yang J
    Am J Transl Res; 2021; 13(12):13815-13824. PubMed ID: 35035721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.
    Trudo F; Kern DM; Davis JR; Tunceli O; Zhou S; Graham EL; Strange C; Williams SA
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2055-66. PubMed ID: 26451101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to controller therapy for chronic obstructive pulmonary disease: a review.
    Charles MS; Blanchette CM; Silver H; Lavallee D; Dalal AA; Mapel D
    Curr Med Res Opin; 2010 Oct; 26(10):2421-9. PubMed ID: 20815661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tiotropium/Olodaterol: A Review in COPD.
    Dhillon S
    Drugs; 2016 Jan; 76(1):135-46. PubMed ID: 26683033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACP Journal Club. Review: In COPD, tiotropium improves lung function and reduces adverse events compared with ipratropium bromide.
    Maselli DJ; Peters JI
    Ann Intern Med; 2016 Jan; 164(2):JC6. PubMed ID: 26784496
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E; Brusselle GG; Joos GF
    Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of chronic obstructive pulmonary disease.
    Barr RG
    JAMA; 2004 Mar; 291(9):1066-7; author reply 1067. PubMed ID: 14996770
    [No Abstract]   [Full Text] [Related]  

  • 38. Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD.
    Magnussen H; Tetzlaff K; Bateman ED; Watz H; Kirsten AM; Wouters EF; Disse B; Finnigan H; Rodriguez-Roisin R; Calverley PM
    Eur Respir J; 2016 Feb; 47(2):651-4. PubMed ID: 26585433
    [No Abstract]   [Full Text] [Related]  

  • 39. Tiotropium step-up therapy in asthma.
    Miller DR; Chetty M; Currie GP
    N Engl J Med; 2011 Feb; 364(6):578; author reply 578-9. PubMed ID: 21306256
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical and economic outcomes associated with the use of fluticasone propionate 250 mcg and salmeterol 50 mcg combination versus tiotropium bromide 18 mcg as initial maintenance treatment for chronic obstructive pulmonary disease in managed care.
    Bell CF; Coutinho AD; Farrelly E; Lokhandwala T; Landsman-Blumberg P
    J Med Econ; 2018 Jun; 21(6):629-638. PubMed ID: 29577787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.